New hope for chinese transplant patients: ruxolitinib targets severe immune reaction

NCT ID NCT06462469

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 33 times

Summary

This study tests the drug ruxolitinib in Chinese patients aged 12 and older who have a serious immune reaction called acute graft-versus-host disease (aGvHD) after a stem cell transplant, and whose condition did not improve with steroids. The goal is to see if ruxolitinib can control the disease by reducing symptoms. About 36 participants will take ruxolitinib pills, and doctors will check their response after 28 and 56 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site
RECRUITING

Guangzhou, Guangdong, 510515, China
Novartis Investigative Site
RECRUITING

Zhengzhou, Henan, 450003, China
Novartis Investigative Site
RECRUITING

Wuhan, Hubei, 430030, China
Novartis Investigative Site
RECRUITING

Changchun, Jilin, 130021, China
Novartis Investigative Site
RECRUITING

Xian, Shanxi, 710061, China
Novartis Investigative Site
RECRUITING

Chengdu, Sichuan, 610072, China
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310003, China
Novartis Investigative Site
RECRUITING

Beijing, 100028, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Beijing, 100039, China
Novartis Investigative Site
RECRUITING

Beijing, 100070, China
Novartis Investigative Site
RECRUITING

Dalian, 116000, China
Novartis Investigative Site
RECRUITING

Fuzhou, 350001, China
Novartis Investigative Site
RECRUITING

Shanghai, 200025, China
Novartis Investigative Site
RECRUITING

Taian, 271099, China
Novartis Investigative Site
RECRUITING

Tianjin, 300020, China

Conditions

Explore the condition pages connected to this study.

STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE